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Abstract 
Background: MicroRNAs (miRNAs) are noncoding RNAs that control the expression of their target mRNAs. It 
affects cancer cell proliferation and apoptosis as oncogenes or tumor suppressors. Dysregulation of miRNAs 
expression leads to the development of various cancers. Therefore, for the first time in this field, this study 
investigated the effect of overexpression of microRNA-630 on the Jurkat cells. 
Materials and methods: : In this experimental study, the Jurkat cells were divided into the four groups, i.e. 
non-transfected control group (A), scramble (B), transfected with 50 nM concentrations of miR-630 (C), and 
treated with 100 nM miR-630 (D). MiR-630 transfection was performed by lipofectamine 2000. Cancer cell 
growth in each group was analyzed with MTT assay. Flow cytometry investigated percent of viable, necrotic, 
and apoptotic cells. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) measured 
the expression of P53, P21, and BCL2 genes. SPSS (version 21) especially Kruskal-Wallis and Mann-Whitney 
U tests were utilized for data analysis. 
Results: The results of MTT assay showed that the cell growth rates in C (118%) and D (136%) groups were 
significantly higher than that in the control group (P= 0.037 vs. 0.034). The percentage of early and late 
apoptosis in C (3.1% P=0.01, 4.2% P=0.02) and D (0.5% P=0.008, 0.4% P=0.006) groups were significantly 
lower than those in the control group. The expression of p53 and p21 in C (0.7 P=0.037, 0.62 P=0.034) and D 
(0.44 P=0.034, 0.53 P=0.038) Groups were significantly decreased compared with the control group. The 
expression of B-cell lymphoma-2 (Bcl2) in C (1.85) and D (3.26) groups were significantly increased compared 
with the control group (P= 0.037 vs. 0.024). 
Conclusion: Overexpression of miR-630 led induction of T-ALL cell growth and reduction of their apoptosis. 
These results emphasized that miR-630 contributed as an oncogenic microRNA in T-ALL cells.  
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Introduction 
Acute lymphoblastic leukemia (ALL) is 
the most common type of childhood cancer 
that often occurs at 2 to 5 years of age. 
Increasing of cancerous B and T lymphoid 
precursors in the bone marrow is the major 
component of ALL (1). Almost 35% of 
patients aged 18 to 60 years old stay alive 
and their treatment process has been slow 
(2). Environmental (especially benzene 
and ionizing radiation), cytogenetic, 
epigenetic, and infection can be the cause 
of ALL (3-5). Finding novel therapy is 
extremely important because drug toxicity, 
resistance to chemotherapy and 
radiotherapy or relapse are the weaknesses 
of current treatments (6- 8). 
T cell acute lymphoblastic leukemia (T-
ALL) is the malignancy of immature T 
cell. It is 10%–15% of pediatric cancers 
and 25% of adult ALL cases. T-ALL in 
children and juvenile has a good prognosis 
and 60-75% of them have 5 years of 
relapse-free survival rate (9). T-ALL can 
be classified into different molecular 
genetic subtypes. Patients with T-ALL 
have a higher risk than B-precursor ALL 
for relapse (10). 
MicroRNAs (miRNAs or miRs) are 
defined as 21–25 nucleotide RNA 
molecules that bind to the 3' untranslated 
region (UTR) and regulate the expression 
of mRNAs (11, 12). MiRNAs mainly 
modulate mRNA stability and protein 
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translation, thereby exerting post-
transcription effects (11, 13). MiRs have a 
specific involvement in cellular 
proliferation and apoptosis (14-16). 
Different expressions of special miRs 
might become a master key for the 
diagnosis and treatment of malignancy 
(17). 
MiR-630 is a type of micro-RNA that has 
22 nucleotides and acts through its various 
signaling pathways to inhibit or 
inductance, thereby contributing to the 
improvement or progression of certain 
cancers. Depending on the tumor types, 
miR-630 has reportedly functioned as a 
tumor-suppressive or an oncogenic 
miRNA. In some malignancies, 
overexpression of miR-630 is associated 
with proliferation, invasion, and 
metastases (18, 19) but it induced cancer 
cell apoptosis in another form of 
malignancy (20-22). Recently, it has been 
shown that various types of leukemia, such 
as ALL, have different expressions of 
microRNA, and this is promising potential 
biomarker for diagnosis and prognosis (23-
28). It has also been shown that the 
expression of different microRNAs is 
related to the rate of survival and 
prognosis in ALL (24). Previous studies 
have expressed the effects of miR-630 on 
solid tumors, such as pancreatic 
tumors(29), prostate(30), and colon 
cancer(31). However, the function of 
miRNA 630 is not specified in T ALL 
disease. 
The present research aimed to examine the 
proliferation and viability of the T ALL 
cell line (Jurkat) after overexpression of 
miR-630. Besides, the effect of this 
miRNA on P53 pathway genes like P21, 
P53, and prosurvival B-cell lymphoma-2 
(BCL-2) was investigated by quantitative 
real-time polymerase chain reaction (qRT-
PCR). 
 
Materials and Methods 
Cell culture 
This study was accomplished at the 
Bushehr University of Medical Sciences 
(research ethics code: 
IR.BPUMS.REC.1396.66). The Jurkat cell 
line was obtained from the Iranian Stem 
Cell Technology Research Center (Tehran, 
Iran). It cultured in RPMI-1640 (CBSA; 
cell biotechnology saba arna, Fars, Iran) 
supplemented with 10% fetal bovine 
serum (Gibco; Thermo Fisher Scientific, 
Inc., Waltham, USA) and 1% antibiotic-
antimycotic 100x (caisson; caisson 
laboratories, Inc., Smithfield, USA) at 
37˚C in a 5% CO2 humidified incubator. 
Finally, suspension cultured cells were 
used for transfection at ~80% 
confluence(32). 
Transfection 
The Jurkat cell lines were divided into the 
following four groups, i.e. non-treated 
control group (A), scramble (B), treated 
with 50 nM concentrations of miR-630 
(C), and treated with 100 nM miR-630 
(D). (Eurofins Genomics, Germany). Cells 
were cultured in 96-well plate (4×10 4 
cells/well) in 85% humidified and 5% 
CO2. The first stage was done one day 
before transfection, where Jurkat cells 
were seeded in 24-well plates at a 
concentration of 2×105 cells/well in 
medium with serum, but without 
antibiotics. In the second stage, miR-630 
was diluted in 50 μl OptiMEM (Gibco, 
USA) in two tubes. After that, 
Lipofectamine 2000 (Invitrogen; Thermo 
Fisher Scientific, Inc. USA) (1.5 μl) was 
diluted into 50 μl OptiMEM and incubated 
it for 5 min at room temperature. Next, the 
diluted miR-630 from stage 2 was mixed 
with the diluted Lipofectamine 2000 from 
stage 3. The compound incubated at room 
temperature for 20 min. Then, miR-630-
Lipofectamine 2000 complexes from stage 
4 (100 μl) added directly to each well-
containing cells (from stage 1), and mixed 
the compound gently by rocking the plate 
back and forth. Finally, the compound was 
incubated at 37
o
C in a CO
2 
incubator. Non-
transfected Jurkat cell line was considered 
as the control group. siRNA conjugated 
with FITC (Santa Cruz Biotechnology, 
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Inc. Texas, USA) was utilized as a 
scramble to closely monitor the 
transfection states.  
 
Cell growth assessment 
MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide) solution (10 
µl from 5 mg/ml stock) was added to the 
wells 48 hours after transfection. The cells 
were incubated for 4 hours at 37°C. Then, 
the medium was discarded and 150 μl of 
DMSO was added to each well, and plates 
were shaken for 15 min. The absorbance of 
generated formazan was quantified by 
spectrophotometry (ELISA reader) at 570 
nm. Three independent experiments were 
performed in triplicate. 
Cell apoptosis assay 
Jurkat cells were cultured in 48-well plates 
(8× 104 cells/well) in antibiotic-free medium 
and transfected. After 48 hours, cells were 
collected, washed twice, and stained with 
FITC-Annexin V and 7-AAD using the 
FITC-Annexin V Apoptosis Detection Kit 
with 7-AAD (BioLegend, San Diego, CA; 
USA) according to the manufacturer’s 
manual (33). First, cells were washed with 
cold BioLegend's cell staining buffer and 
then re-suspended in binding buffer. 
Subsequently, cells were incubated with 5 
μl Annexin V/FITC and 5 μl 7-AAD for 
15 min at room temperature in the dark. 
Then, 400 µl of Annexin V binding buffer 
was added to each tube of the cell. 
FACSCalibur flow cytometer (BD 
Bioscience, USA) measured apoptotic 
cells. Three independent experiments were 
performed. 
RNA extraction 
Total RNA was extracted from cells in 
different groups using Total RNA isolation 
kit (Santa Cruz Biotechnology, Inc., 
Texas, USA) and according to the 
manufacturer's manual. RNA 
concentration was determined after 
extraction using a Nanodrop 
spectrophotometer (Thermo Fisher 
Scientific, Inc., USA) and electrophoresis 
on 2% agarose gel. 
 
 
 
cDNA Synthesis and reverse 
transcription-quantitative 
polymerase chain reaction 
(RT-qPCR) 
cDNA of miR and other genes were 
generated using a  high sensitive cDNA 
Synthesis kit (BONbiotech, Inc. Iran) and 
cDNA Synthesis H Minus First Strand 
Revert Aid kit (Thermo Fisher Scientific, 
Inc. USA), respectively and according to 
the manufacturer's manual. Specific 
primers for PCR amplification were 
synthesized by Bonbiotech Company 
(Bonbiotech, Inc, Iran) as represented in 
Table I. The expression level of miR-630 
and mRNA in the cells were confirmed on 
the Step One Plus Real-Time PCR systems 
(ABI, US). By using a 2X Real MOD 
Green PCR Master Mix kit (Takara Bio, 
Inc., Otsu, Japan), expressions of P53, 
P21, and BCL2 mRNA in Jurkat cells were 
quantified. To put it in a nutshell, in a final 
volume of 20 µl, containing 10 pmol of 
each primer, 10 µl 2× reaction mixture of 
SYBR Green and 7.4 µl sterile deionized 
water, 2 µl cDNA product was diluted 
(34). The cycling program was as follows: 
an initial denaturation step at 95°C for 10 
min, followed by 40 cycles including a 
denaturation step at 95°C for 10 sec, 
annealing, and extension at 55˚C for 40 
sec. Hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT) and 
U6 snRNA were selected as internal 
housekeeping controls. All PCRs were 
performed in triplicate. The relative 
expression levels of miR-630 and P53, 
P21, and Bcl2  mRNA were calculated by 
the 2
-ΔΔCT 
method (35). 
Statistical analysis 
 Results were expressed as the mean ± 
standard deviation (SD) and analyzed 
using SPSS (v. 21.0) (SPSS, Inc. Chicago, 
IL, USA). Differences between groups 
were evaluated by Kruskal-Wallis tests, 
and a comparison of studied groups for the 
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expression of the desired genes was 
assessed by Mann-Whitney U tests. 
P<0.05 was considered to indicate a 
statistically significant difference (34). 
 
Results 
Transfection accuracy  
Six hours after transfection, the scramble 
group (absorbance: 490 nm, emission: 514 
nm) was examined by a green filter 
fluorescent microscope. The transfection 
accuracy was assured by observing the 
greenlight fluorescein inside the cells 
(Figure 1). 
The effect of miR-630 on cell 
growth  
The cell growth means of studied groups 
with triple repetition are presented in Table 
II and Figure 2. The MTT assay showed 
that the growth of scramble group was not 
significantly different from that of the 
control group (P =0.48). In addition, 
upregulation of miR-630 significantly 
stimulated the proliferation of C and D 
groups compared with the negative control 
group (P=0.037, 0.034). The growth rate 
was significantly different between C and 
D groups (P=0.046).  
Reduction of cell apoptosis 
following overexpression of miR-
630  
The place of viable, apoptotic, and necrotic 
cells in flow cytometry quadrant 
(according to the type of absorbent stains) 
are given in Table III. The percentage of 
the viable cells in C and D groups was 
90.5% and 97.6%, respectively.  
By increase of the miR-630 transfection, 
the viable cells increased significantly 
compared with the control group and the 
scramble. * p<0.05. 
Viable cells in C and D groups were 
significantly different compared with 
control (P= 0.034, 0.022 respectively). As 
shown in Figure 3, the percentage of live 
cells increased with increase of miR-630 
transfection doses. Early apoptotic cells in 
C and D groups were significantly 
different compared with control (P=0.01 
and 0.008 respectively). Also, late 
apoptotic cells in C and D groups were 
significantly different compared with 
control (P=0.02 and 0.006 respectively). 
According to Figure 5, the percentage of 
necrotic cells was decreased by elevating 
of miR transfection doses; whereas, C and 
D groups didn’t has significant difference 
compared with control (P=0.38 and 0.24 
respectively) and there wasn’t significant 
difference between C and D groups in 
necrotic cells (P=0.5). There were 
significant difference between C and D 
groups in viable, early apoptotic, and late 
apoptotic cells (P=0.037, 0.03, and 0.02 
respectively). 
Overexpression of miR-630 in 
treated groups 
 Fold changes of the miR-630 in C (50 
nM) and D (100 nM) groups were 4.4 and 
12.7, respectively. The expression of miR 
in C and D groups were significantly 
different compared with control (P=0.037, 
0.037). In addition, there was a significant 
difference between C and D groups 
(P=0.04). The cycle threshold of target 
miR was normalized against U6 as an 
internal control. The fold change is 
presented in Figure 6 and Table IV. 
The expression of miR-630 in C (50 nM) and 
D (100 nM) groups increased significantly 
compared to the control. This finding 
confirmed accuracy of miR transfection. * 
p<0.05. 
Inducing Bcl2 gene expression 
following overexpression of 
miR-630 
Fold changes in the expression of p21, 
p53, and Bcl2 are shown in Table IV and 
Figure 7. The cycle threshold of target 
genes was normalized against HGPRT as a 
reference gene. Results demonstrated that 
Bcl2 gene expression increased following 
elevation of miR-630 (fold changes were 
1.86 and 3.26 in C and D groups 
respectively). Bcl2 expression was 
increased significantly in C and D groups 
compared with control (P=0.037 vs. 
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0.024). There was a significant difference 
between C and D groups (P=0.04). 
Reduction of p53 gene expression 
in transfected cells  
As shown in Table IV and Figure 7, the 
gene expression of p53 were 0.7 and 0.44 
in C and D groups respectively. The 
expression were downregulated 
significantly in C and D groups compared 
with control (P= 0.037, 0.034 respectively) 
.In addition, the gene expression in C 
group was significantly higher than that in 
D group (P=0.04). 
The Effect of miR-630 
upregulation on the expression of 
p21 
According to Figure 7, fold changes were 
0.62 and 0.53 in C and D groups 
respectively, so the relative gene 
expression of p21 was significantly 
downregulated in C and D groups 
compared with control (P= 0.034 vs. 
0.038). There was no significant difference 
between C and D groups (P=0.06). The 
expression of Bcl2 was increased significantly 
in C (50 nM) and D (100 nM) groups 
compared with control. The expression of p53 
and p21 were downregulated significantly in C 
and D groups compared with control (p<0.05).  
 
 
 
Table I: Sequence of Real-Time PCR primers 
Primer Sequence Direction Gene 
5'-TAAAGGAGGAAGATAAGG-3'  
F 
 
MicroRNA-630 
5'-GTAGCAGTGATAGGCATT-3' R  
5'-CTCGCTTCGGCAGCACATATAC-3' F U6 small nuclear RNA 
5'-ACGCTTCACGAATTTGCGTGTC-3' R  
5'-TAACAGTTCCTGCATGGGCGGC-3' F P53 
5'-AGGACAGGCACAAACACGCACC-3' R  
5'-GAGGCCGGGATGAGTTGGGAGGAG-3' F P21 
5'-CAGCCGGCGTTTGGAGTGGTAGAA-3' R  
5'-GGTGGGGTCATGTGTGTGG-3' F Bcl 2 
5'-CGGTTCAGGTACTCAGTCATCC-3' R  
5'-GGACAGGACTGAACGTCTTG-3' F HGPRT 
5'-ATAGCCCCCCTTGAGCACAC-3 R  
   
HGPRT, Hypoxanthine-guanine phosphoribosyl transferase; Bcl2, B-cell lymphoma 2  F, forward; 
R, reverse 
 
 
Table II: The growth rate of Jurkat cells  
Non treated Treated 
Scramble (B) 50 nM (C) 100 nM (D) 
97 ±4.5 118 ±3.0 136 ±2.8 
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Table III: Place of viable, apoptotic, and necrotic cells in the flow cytometry quadrant according to 
the type of absorbent stains 
7-AAD Annexin-V stain 
  Cell Condition 
Neg Neg Viable (Q1) 
Neg Pos Early Apoptotic (Q2) 
Pos Pos Late Apoptotic (Q3) 
Pos Neg Necrotic (Q4) 
  Pos; Positive, Neg; Negative 
 
 
. 
Table IV: The Expression of miR-630, pro-apoptotic genes, and anti-apoptotic genes in cell groups 
Gene miR-630 P53 P21  
Bcl2 
 
Group 
 
    
Scramble (B) 1.09±0.100 1.20± 0.050 1.06±0.090 1.02±0.060 
50 nM (C) 4.40±0.900 0.70±0.015 0.62±0.010 1.85±0.055 
100 nM (D) 
 
12.70±1.100 0.44±0.011 0.53±0.011 3.26±0.200 
 
 
 
 
Figure 1. Greenlight of FITC attached to siRNA in the scramble sample 
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Figure 2. T-ALL cell growth in four groups 
 
Figure 3. The effect of miR-630 on the apoptosis of Jurkat cells Flow cytometry analysis of A. 
Control group, B. Scramble, C. transfected by 50 nM of miR-630 and D. transfected by 100 nM of 
miR-630 
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 Figure 4. Viable cell in treated and non-treated groups (%) 
  
 
 Figure 5. Percentage of early and late apoptotic and necrotic cells in Q2, Q3, Q4 
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Figure 6. Relative expression of miR-630 in treated and non-treated cell groups. 
 
 
 
Figure 7. The relative expression of pro-apoptotic and anti-apoptotic genes in treated and non-treated 
groups 
 
 
Discussion 
Immunophenotypic characterization of 
According to recent studies, cancer cell 
growth or apoptosis is modulated 
following the dysregulation of miRNAs 
(36). Aberrant expression of miRNAs was 
specified but an interesting question is, 
through which molecular pathway does the 
miR intervene? (37). Depending on the 
tumor types, miR-630 has reportedly 
functioned as a tumor-suppressive or an 
oncogenic miRNA. In some malignancies, 
overexpression of miR-630 was associated 
with proliferation and invasion (18, 19), 
but it induced cancer cell apoptosis in 
another form of malignancy (20-22). In 
this study, to further investigate the effects 
of miR 630 on T ALL, Jurkat cells were 
transfected with miR 630, which induced 
overexpression of miR 630. In the present 
study, MTT assessed that the cancer cell 
growth in miR treated groups was 
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significantly higher than that in the control 
group. Increase of the miR transfected 
dosage from 50 to 100 nM significantly 
induced proliferation. Hence, it proved that 
overexpression of miR-630 implicated as 
an oncogene in boosting cell growth and 
proliferation. Flow cytometry 
demonstrated that the viable cells rose to 
97.6% in the 100 nM group. The number 
of cells into the primary and secondary 
apoptosis phase had a significant decrease 
in both doses compared to control and 
compared with each other, but necrosis 
changes were not significant in different 
groups. In general, overexpression of miR-
630 could increase the number of viable 
cells and led to a decrease in apoptosis.  
In previous studies, the increase or 
decrease of miR-630 in some cancer cell 
lines led to an increase in growth or an 
increase in cell apoptosis. For example, 
Sakurai et al in 2014 showed that 
upregulation of exogenous miR-630 in 
prostate cancer cells (PC3) stopped the 
growth of these cells(30). In a study by 
Zhou et al., the proliferation and invasion 
of cancer cells were reduced following 
overexpression of miR-630 in the 
gonadotropic cell line due to inhibition of 
Sox4(38). Corcoran et al,m in 2014 proved 
that upregulation  of miR-630 in the 
HER2-resistant breast cancer cell line 
decreased invasion and migration, but 
inhibition of this miR to an increase in 
invasion (39). In another study on breast 
cancer cell line, Zhou et al., in 2016 found 
that when the miR-630 was increased, the 
invasion and metastasis of cancer cells 
reduced significantly. They also observed 
decrease of metastases and proliferation 
following increase of this miR in the 
animal phase and cell line (40). Jin et al., 
in 2016 found that overexpression of miR-
630 in esophageal squamous cell 
carcinoma cell lines suppressed 
proliferation and metastasis. On the 
contrary, knockdown of miR elevated cell 
growth and invasion(41). Studies on other 
cell lines showed that this miR could also 
act as an oncogene. For example, Zhou et 
al., in 2014 and 2016 revealed that 
expression of miR-630 significantly was 
upregulated in clear cell renal cell 
carcinoma (ccRCC). This overexpression 
was associated with metastasis to lymph 
nodes. On another hand, decrease in miR 
levels caused proliferation and migration 
reduction and increased apoptosis(42, 43). 
Galluzzi et al., in 2010 yielded that 
overexpression of miR-630 reduced lung 
cancer cells apoptosis treated by cisplatin 
(20).  Zou et al., in 2015 investigated the 
ovarian malignant tumor cell line, and 
demonstrated that down-regulation of this 
miR increased apoptosis and reduce the 
proliferation and invasion of cancer cells 
(19). 
The expression of p53, p21 genes induce 
cell growth arrest and apoptosis but Bcl2 
gene inhibit apoptosis (44). As a 
transcription factor, P53 regulates multiple 
cell functions in humans (45). It responds 
to different stressors to transactivate many 
downstream genes, such as p21 and 
PUMA. The p53/p21 complex is created 
through the interaction between P53 and 
P21. Then, it binds to prosurvival BCL-2 
family proteins (apoptosis regulator) to 
liberate pro-apoptotic groups, such as Bax 
and Bak, which in turn promotes apoptosis 
or cycle arrest (46-48). In many cancers, 
the functions of p53 pathway components, 
such as p21 and p53, have been disrupted. 
Many studies showed that miRNAs might 
target components of this pathway and 
potentially inhibit their expression, thereby 
increasing malignancies (45, 46). 
Moreover, Bcl2 acts as an apoptosis 
regulator and has been shown to play a 
critical role in the pathogenesis of different 
malignancies (34). These proteins are 
important because studies suggested that 
miRs could exert their oncogenic or 
suppressive effects by inhibition or 
induction of these genes (29, 49-51). For 
example, Galluzzi et al., in 2010 studies 
lung cancer cell line (A549), and 
concluded that overexpression of miR-630 
by reduction of PARP3 / DDIT4 / EP300 
was associated with modulation of 
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apoptosis (20). In a study by Zhang et al., 
in 2015 on 6 types of colorectal cancer cell 
lines, it was shown that the up-regulation 
of  miR-630 had effects on p53 and Bcl2 
levels (52).  
In the present study, the results of real-
time PCR indicated that fold changes of 
miR-630 was elevated following increase 
of transfection dosage,  but expressions of 
p53 and p21 were decreased significantly. 
In contrast, the expression of Bcl2 was 
increased significantly. It was displayed 
that Bcl2 had a key role in the 
development of cancers (53). Thus, it can 
be concluded that miR-630 is able to affect 
the signaling pathway of pro-apoptotic and 
anti-apoptotic proteins and hence reduce 
apoptosis in the Jurkat cell line. 
 
Conclusion 
Overexpression of miR-630 in Jurkat cells 
could promote cell viability via increasing 
Bcl2 expression. Furthermore, it could 
reduce cell apoptosis by lowering the 
expression of p53. The cell growth and 
proliferation were significantly increased 
in treated groups compared with untreated 
(control) and scramble groups. The 
expression of p21 and p53 genes decreased 
and the expression of Bcl2 gene increased 
significantly following overexpression of 
miR. The study demonstrated that miR-
630 acted as an oncogene in the Jurkat 
cells, which elevated the viability and 
proliferation and reduced the apoptosis of 
cancer cells. Further research is needed to 
define the exact interaction mechanism of 
this miR on the Bcl2 pathway. 
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